Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Ahead
scheduled · today and tomorrow · calendar refreshed 2026-10-13
X-energy, SGL Carbon Announce Capacity Expansion for Nuclear-Grade Graphite
X-energy and SGL Carbon announced an agreement that would expand the supply chain for a critical long-lead material, supporting execution of X-energy's 11+ GW commercial pipeline. The release describes facility upgrades at SGL's Chedde, France site and expanded U.S. machining capacity.
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
Novo Nordisk shares fell after a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events compared with a placebo, a setback for the company's cardiovascular pipeline.
Eversource Energy Reports Second Quarter 2026 Results
Eversource Energy reported second-quarter 2026 "GAAP earnings of $53.7 million, or $0.14 per share," and "Non-GAAP recurring earnings totaled $329.1 million, or $0.87 per share." The company reaffirmed "2026 non-GAAP recurring earnings of between $4.57 per share and $4.72 per share" and a "cumulative long-term earnings per share growth rate within the range of 5 to 7 percent through 2030."
First Solar, Inc. Announces Second Quarter 2026 Financial Results and Reaffirms Guidance
First Solar reported Q2 2026 net sales of $1.06 billion, "a decrease of 4% year-over-year," and net income of $423 million, or $3.92 per diluted share, versus $342 million or $3.18 per diluted share a year earlier. Adjusted EBITDA was $644 million. The company reaffirmed its 2026 guidance and reported a "Contracted sales backlog of 45.1 GW as of June 30, 2026," noting it "surpassed 100 GW of cumulative module sales globally."
Sanofi announced the availability of its half-year financial report for the period ended June 30, 2026, filed with French and US regulators. The release points to Q2 results reporting "Q2 sales growth of 17.8% at CER" and "business earnings per share (EPS) of EUR 2.09," with "2026 guidance upgraded."